Published in Nat Biotechnol on February 01, 2010
Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol (2011) 2.02
HER2 targeted molecular MR imaging using a de novo designed protein contrast agent. PLoS One (2011) 1.09
Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int (2010) 1.05
Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy. Curr Opin Oncol (2010) 1.04
Primary trastuzumab resistance: new tricks for an old drug. Ann N Y Acad Sci (2010) 1.03
Herceptin functionalized microfluidic polydimethylsiloxane devices for the capture of human epidermal growth factor receptor 2 positive circulating breast cancer cells. Biomicrofluidics (2010) 1.02
68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur J Nucl Med Mol Imaging (2011) 0.97
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget (2013) 0.97
Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery. Eur J Nucl Med Mol Imaging (2013) 0.96
Quantitative high-resolution genomic analysis of single cancer cells. PLoS One (2011) 0.96
Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. Histopathology (2011) 0.95
In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers. PLoS One (2012) 0.94
Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta (2012) 0.91
Reinventing clinical trials. Nat Biotechnol (2012) 0.90
Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents. J Biol Inorg Chem (2013) 0.88
Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press) (2015) 0.86
Affibody-DyLight conjugates for in vivo assessment of HER2 expression by near-infrared optical imaging. PLoS One (2012) 0.84
The epidermal growth factor receptor conundrum. Cancer (2010) 0.83
Serum HER2 Is a Potential Surrogate for Tissue HER2 Status in Gastric Cancer: A Systematic Review and Meta-Analysis. PLoS One (2015) 0.82
In vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment. Clin Cancer Res (2014) 0.81
US pharmacies broaden access to pharmacogenetic tests. Nat Biotechnol (2010) 0.80
Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH. Gastric Cancer (2015) 0.80
Development of NIST standard reference material 2373: Genomic DNA standards for HER2 measurements. Biomol Detect Quantif (2016) 0.79
Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.79
Oncogenic HER2 fusions in gastric cancer. J Transl Med (2015) 0.78
In vivo assessment of HER2 receptor density in HER2-positive tumors by near-infrared imaging, using repeated injections of the fluorescent probe. Technol Cancer Res Treat (2013) 0.78
GRPR-targeted Protein Contrast Agents for Molecular Imaging of Receptor Expression in Cancers by MRI. Sci Rep (2015) 0.77
Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers. J Natl Cancer Inst (2014) 0.76
Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines. Sci Rep (2017) 0.75
Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma. Diagnostics (Basel) (2013) 0.75
Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer (2009) 2.63
Trastuzumab: a picky partner? Clin Cancer Res (2009) 1.60
FDA transparency rules could hit small companies hardest. Nat Biotechnol (2010) 4.46
Myriad decision reassures biotechs but diagnostics still murky. Nat Biotechnol (2011) 3.62
Trouble at the office. Nat Biotechnol (2008) 2.12
Bristol-Myers Squibb swallows last of antibody pioneers. Nat Biotechnol (2009) 1.79
NCATS launches drug repurposing program. Nat Biotechnol (2012) 1.66
Direct-to-consumer genomics reinvents itself. Nat Biotechnol (2012) 1.63
Genzyme backs Osiris, despite Prochymal flop. Nat Biotechnol (2009) 1.47
Genomic testing reaches into the womb. Nat Biotechnol (2013) 1.44
Myriad diversifies, fights rearguard action on patents. Nat Biotechnol (2014) 1.41
Wyeth preemption case ruling sparks labeling confusion. Nat Biotechnol (2009) 1.39
Gunvalson decision sends shockwaves through industry. Nat Biotechnol (2008) 1.38
Genetic testing clamp down. Nat Biotechnol (2010) 1.26
Can web 2.0 reboot clinical trials? Nat Biotechnol (2009) 1.19
Is personalized medicine finally arriving? Nat Biotechnol (2008) 1.16
Hemacord approval may foreshadow regulatory creep for HSC therapies. Nat Biotechnol (2012) 1.02
Biomarker-led adaptive trial blazes a trail in breast cancer. Nat Biotechnol (2010) 1.02
Hedgehog hopes lifted by approval... and stung by failure. Nat Biotechnol (2012) 1.01
Industry welcomes Genetic Information Nondiscrimination Act. Nat Biotechnol (2008) 0.99
Nature Biotechnology's academic spinouts of 2013. Nat Biotechnol (2014) 0.93
Avastin's commercial march suffers setback. Nat Biotechnol (2010) 0.91
Can cancer clinical trials be fixed? Nat Biotechnol (2011) 0.91
Reinventing clinical trials. Nat Biotechnol (2012) 0.90
PML problems loom for Rituxan. Nat Biotechnol (2010) 0.88
Diagnostics firms face new patent claim worries. Nat Biotechnol (2009) 0.86
Stromedix acquisition signals growing interest in fibrosis. Nat Biotechnol (2012) 0.83
As Genzyme flounders, competitors and activist investors swoop in. Nat Biotechnol (2010) 0.81
US pharmacies broaden access to pharmacogenetic tests. Nat Biotechnol (2010) 0.80
Clinical setbacks reduce IGF-1 inhibitors to cocktail mixers. Nat Biotechnol (2012) 0.78
Turning the tide in lung cancer. Nat Biotechnol (2010) 0.78
Regulation of consumer genomic tests remains in limbo. Nat Biotechnol (2009) 0.76
Alliance to bolster translation of academic R&D assets. Nat Biotechnol (2013) 0.75